Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Is Associated with Indigenous American Ancestry in Latin American Women

Autor: Marker, Katie M, Zavala, Valentina A, Vidaurre, Tatiana, Lott, Paul C, Vásquez, Jeannie Navarro, Casavilca-Zambrano, Sandro, Calderón, Mónica, Abugattas, Julio E, Gómez, Henry L, Fuentes, Hugo A, Picoaga, Ruddy Liendo, Cotrina, Jose M, Neciosup, Silvia P, Castañeda, Carlos A, Morante, Zaida, Valencia, Fernando, Torres, Javier, Echeverry, Magdalena, Bohórquez, Mabel E, Polanco-Echeverry, Guadalupe, Estrada-Florez, Ana P, Serrano-Gómez, Silvia J, Carmona-Valencia, Jenny A, Alvarado-Cabrero, Isabel, Sanabria-Salas, María Carolina, Velez, Alejandro, Donado, Jorge, Song, Sikai, Cherry, Daniel, Tamayo, Lizeth I, Huntsman, Scott, Hu, Donglei, Ruiz-Cordero, Roberto, Balassanian, Ronald, Ziv, Elad, Zabaleta, Jovanny, Carvajal-Carmona, Luis, Fejerman, Laura, COLUMBUS Consortium

Publikováno v: Cancer research, vol 80, iss 9

Women of Latin American origin in the United States are more likely to be diagnosed with advanced breast cancer and have a higher risk of mortality than non-Hispanic White women. Studies in U.S. Latinas and Latin American women have reported a high i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::ac50ee5675a0cd3014571f713a96f263
https://escholarship.org/uc/item/8628w2w7

Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Is Associated with Indigenous American Ancestry in Latin American Women.

Autor: Marker KM; Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, California.; Division of Epidemiology, School of Public Health, University of California Berkeley, Berkeley, California., Zavala VA; Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, California., Vidaurre T; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru., Lott PC; UC Davis Genome Center, University of California, Davis, Davis, California., Vásquez JN; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru., Casavilca-Zambrano S; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru., Calderón M; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru., Abugattas JE; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru., Gómez HL; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru., Fuentes HA; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru., Picoaga RL; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru., Cotrina JM; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru., Neciosup SP; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru., Castañeda CA; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru., Morante Z; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru., Valencia F; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru., Torres J; Unidad de Investigación en Enfermedades Infecciosas, Instituto Mexicano del Seguro Social; México City, México., Echeverry M; Grupo de Citogenética, Filogenia y Evolución de Poblaciones, Facultades de Ciencias y Facultad de Ciencias de la Salud, Universidad del Tolima, Ibagué, Colombia., Bohórquez ME; Grupo de Citogenética, Filogenia y Evolución de Poblaciones, Facultades de Ciencias y Facultad de Ciencias de la Salud, Universidad del Tolima, Ibagué, Colombia., Polanco-Echeverry G; UC Davis Genome Center, University of California, Davis, Davis, California., Estrada-Florez AP; UC Davis Genome Center, University of California, Davis, Davis, California.; Grupo de Citogenética, Filogenia y Evolución de Poblaciones, Facultades de Ciencias y Facultad de Ciencias de la Salud, Universidad del Tolima, Ibagué, Colombia., Serrano-Gómez SJ; Grupo de Investigación en Biología del Cáncer, Instituto Nacional de Cancerología, Bogotá, Colombia., Carmona-Valencia JA; Dinamica IPS, Medellín, Colombia., Alvarado-Cabrero I; Hospital de Oncología de Centro Médico Nacional Siglo XXI, México City, México., Sanabria-Salas MC; Subdirección de Investigaciones - Instituto Nacional de Cancerología, Bogotá, Colombia., Velez A; Dinamica IPS, Medellín, Colombia.; Hospital Pablo Tobon Uribe, Medellín, Colombia., Donado J; Hospital Pablo Tobon Uribe, Medellín, Colombia., Song S; Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, California., Cherry D; Department of Medicine, University of California San Diego, San Diego, California., Tamayo LI; Department of Public Health Sciences, University of Chicago, Chicago, Illinois., Huntsman S; Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, California., Hu D; Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, California., Ruiz-Cordero R; Department of Pathology, University of California, San Francisco, California., Balassanian R; Department of Pathology, University of California, San Francisco, California., Ziv E; Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California., Zabaleta J; Stanley S. Scott Cancer Center, LSUHSC, New Orleans, Louisiana.; Department of Pediatrics, LSUHSC, New Orleans, Louisiana., Carvajal-Carmona L, Fejerman L; Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, California. laura.fejerman@ucsf.edu.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

Publikováno v: Cancer research [Cancer Res] 2020 May 01; Vol. 80 (9), pp. 1893-1901. Date of Electronic Publication: 2020 Apr 03.